Crossmark

Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study)

Crossref DOI link: https://doi.org/10.1007/s10840-020-00884-x

Published Online: 2020-09-28

Published Print: 2020-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Flores-Umanzor, Eduardo Josué

Cepas-Guillen, Pedro L.

Arzamendi, Dabit

Cruz-González, Ignacio

Regueiro, Ander

Freixa, Xavier
Funding

Funding for this research was provided by:

Sociedad Española de Cardiología (Interventional Cardiology Scholarship Dr. Alfonso Medina of the Spanish Society of Cardiology.)

NewBristol Myers Squibb/Pfizer Alliance, within the European Thrombosis Investigator-Initiated Research Program
License Information

Text and Data Mining valid from 2020-09-28

Version of Record valid from 2020-09-28
More Information

Article History

Received: 6 July 2020

Accepted: 21 September 2020

First Online: 28 September 2020

Compliance with ethical standards

: The study was approved by the Ethics Committee of each center and adhered to the principles outlined in the Declaration of Helsinki.

: XF, IC, and DA are proctors for Abbott Medical.

Document is current

Any future updates will be listed below